Baudax Bio Wins FDA Approval for Anjeso, a Non-Opioid Pain Treatment

Shares of Pennsylvania-based Baudax Bio are up more than 40% in premarket trading after the company announced its pain medication Anjeso was greenlit by the U.S. Food and Drug Administration.